Chinese pharmaceutical firm, Shanghai Green Valley Pharmaceuticals, has gained conditional approval from the country’s regulatory agency for oligomannate as a treatment for mild-to-moderate Alzheimer’s disease.
Browsing: gut microbiome
Four studies presented at SfN Neuroscience have demonstrated how the microbiome interacts with the brain in mice, revealing the possible mechanisms behind gut–brain communication.
A new mouse model of Parkinson’s has demonstrated how the disease could spread from the gut to the brain through the vagus nerve.
Long-term antibiotic treatment may reduce the size of amyloid plaques and could alter the appearance of microglia in the brains of male mice.
In this interview, we spoke with Viviane Labrie about her research into the vermiform appendix as a possible contributor to Parkinson’s disease.
Researchers have revealed that a stroke could alter an individual’s microbiome even up to 1 month after it occurs; this has emphasized the importance of incorporating gut health in patient recovery and treatment.
Whilst at SfN 2018, we had the pleasure of speaking with Subhash Kulkarni about advances in enteric neurobiology, including challenges and future outlook.
In this interview, we spoke with Giovanni Frisoni about his talk on gut microbiome alterations and what impact this research could have for patients.
Researchers at AAIC have reported new data on how the gut microbiome and lipid metabolism may influence Alzheimer’s and other brain diseases.